| General Information | |
|---|---|
| ZINC ID | ZINC000040402377 |
| Molecular Weight (Da) | 422 |
| SMILES | O=C(NCCC(c1ccccc1)c1ccccc1)C(O)(c1ccccc1)c1ccccc1 |
| Molecular Formula | C29N1O2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.612 |
| HBA | 2 |
| HBD | 2 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 32 |
| LogP | 5.612 |
| Activity (Ki) in nM | 2187.76 |
| Polar Surface Area (PSA) | 49.33 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | - |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | - |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.933 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 24 |
| Fraction csp3 | 0.14 |
| Ilogp | 3.6 |
| Xlogp3 | 5.83 |
| Wlogp | 5.15 |
| Mlogp | 4.74 |
| Silicos-it log p | 5.97 |
| Consensus log p | 5.06 |
| Esol log s | -6.09 |
| Esol solubility (mg/ml) | 0.000345 |
| Esol solubility (mol/l) | 0.00000081 |
| Esol class | Poorly sol |
| Ali log s | -6.64 |
| Ali solubility (mg/ml) | 0.0000973 |
| Ali solubility (mol/l) | 0.00000023 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.18 |
| Silicos-it solubility (mg/ml) | 2.77E-08 |
| Silicos-it solubility (mol/l) | 6.58E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.73 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 2.66 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.701 |
| Logd | 3.55 |
| Logp | 5.393 |
| F (20%) | 1 |
| F (30%) | 0.118 |
| Mdck | - |
| Ppb | 96.92% |
| Vdss | 1.241 |
| Fu | 1.16% |
| Cyp1a2-inh | 0.052 |
| Cyp1a2-sub | 0.094 |
| Cyp2c19-inh | 0.939 |
| Cyp2c19-sub | 0.818 |
| Cl | 2.169 |
| T12 | 0.137 |
| H-ht | 0.643 |
| Dili | 0.219 |
| Roa | 0.014 |
| Fdamdd | 0.936 |
| Skinsen | 0.138 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.067 |
| Bcf | 1.663 |
| Igc50 | 4.336 |
| Lc50 | 4.472 |
| Lc50dm | 4.19 |
| Nr-ar | 0.05 |
| Nr-ar-lbd | 0.058 |
| Nr-ahr | 0.584 |
| Nr-aromatase | 0.008 |
| Nr-er | 0.642 |
| Nr-er-lbd | 0.01 |
| Nr-ppar-gamma | 0.015 |
| Sr-are | 0.137 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.002 |
| Sr-mmp | 0.798 |
| Sr-p53 | 0.507 |
| Vol | 470.217 |
| Dense | 0.896 |
| Flex | 0.36 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.408 |
| Synth | 2.108 |
| Fsp3 | 0.138 |
| Mce-18 | 21 |
| Natural product-likeness | -0.434 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |